Standard
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. / Kopple, Joel D; Cheung, Alfred K; Christiansen, Jens Sandahl; Djurhuus, Christian Born; El Nahas, Meguid; Feldt-Rasmussen, Bo; Mitch, William E; Wanner, Christoph; Göthberg, Marie; Ikizler, Talat Alp.
In:
Nephrology, Dialysis, Transplantation, Vol. 26, No. 12, 2011, p. 4095-103.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Kopple, JD, Cheung, AK, Christiansen, JS, Djurhuus, CB, El Nahas, M
, Feldt-Rasmussen, B, Mitch, WE, Wanner, C, Göthberg, M & Ikizler, TA 2011, '
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients',
Nephrology, Dialysis, Transplantation, vol. 26, no. 12, pp. 4095-103.
https://doi.org/10.1093/ndt/gfr363APA
Kopple, J. D., Cheung, A. K., Christiansen, J. S., Djurhuus, C. B., El Nahas, M.
, Feldt-Rasmussen, B., Mitch, W. E., Wanner, C., Göthberg, M., & Ikizler, T. A. (2011).
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients.
Nephrology, Dialysis, Transplantation,
26(12), 4095-103.
https://doi.org/10.1093/ndt/gfr363Vancouver
Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M
, Feldt-Rasmussen B et al.
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients.
Nephrology, Dialysis, Transplantation. 2011;26(12):4095-103.
https://doi.org/10.1093/ndt/gfr363Author
Kopple, Joel D ; Cheung, Alfred K ; Christiansen, Jens Sandahl ; Djurhuus, Christian Born ; El Nahas, Meguid ; Feldt-Rasmussen, Bo ; Mitch, William E ; Wanner, Christoph ; Göthberg, Marie ; Ikizler, Talat Alp. / OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. In: Nephrology, Dialysis, Transplantation. 2011 ; Vol. 26, No. 12. pp. 4095-103.
Bibtex
@article{05fcbfe90f784f88b576c98d6a16cfc1,
title = "OPPORTUNITY{\texttrademark}: a large-scale randomized clinical trial of growth hormone in hemodialysis patients",
abstract = "Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY{\texttrademark} Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.",
author = "Kopple, {Joel D} and Cheung, {Alfred K} and Christiansen, {Jens Sandahl} and Djurhuus, {Christian Born} and {El Nahas}, Meguid and Bo Feldt-Rasmussen and Mitch, {William E} and Christoph Wanner and Marie G{\"o}thberg and Ikizler, {Talat Alp}",
year = "2011",
doi = "http://dx.doi.org/10.1093/ndt/gfr363",
language = "English",
volume = "26",
pages = "4095--103",
journal = "Nephrology, Dialysis, Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "12",
}
RIS
TY - JOUR
T1 - OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients
AU - Kopple, Joel D
AU - Cheung, Alfred K
AU - Christiansen, Jens Sandahl
AU - Djurhuus, Christian Born
AU - El Nahas, Meguid
AU - Feldt-Rasmussen, Bo
AU - Mitch, William E
AU - Wanner, Christoph
AU - Göthberg, Marie
AU - Ikizler, Talat Alp
PY - 2011
Y1 - 2011
N2 - Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY™ Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.
AB - Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY™ Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.
U2 - http://dx.doi.org/10.1093/ndt/gfr363
DO - http://dx.doi.org/10.1093/ndt/gfr363
M3 - Journal article
VL - 26
SP - 4095
EP - 4103
JO - Nephrology, Dialysis, Transplantation
JF - Nephrology, Dialysis, Transplantation
SN - 0931-0509
IS - 12
ER -
